Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | June 10, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2036-06-10 | Direct | 77,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,500 · Balance 77,500 F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2023 Filed Jun 9, 2023 01:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,650 | $0.00 Strike: $6.37 | $0.00 |
DisclosureSEC source: 0000899243-23-014999 · doc4.xml · derivative · entry 7 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires 2033-06-06 F8 · derivative.exercise_date: This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 02, 2023 Filed Jun 9, 2023 01:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 1,583 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014999 · doc4.xml · derivative · entry 6 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,166 Underlying: Common Stock · 1,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F7 · derivative.exercise_date: On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full. F7 · derivative.expiration_date: On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full. Read SEC document |
| June 02, 2023 Filed Jun 9, 2023 01:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 1,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014999 · doc4.xml · nonDerivative · entry 3 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F4 · ownership.direct: Represents 83,716 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| May 02, 2023 Filed Jun 9, 2023 01:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 1,553 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014999 · doc4.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 1,553 Underlying: Common Stock · 1,553 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: The restricted stock units were granted on May 2, 2022 and vest in two equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: The restricted stock units were granted on May 2, 2022 and vest in two equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| May 02, 2023 Filed Jun 9, 2023 01:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 487 | $4.85 | $2,363.95 |
DisclosureSEC source: 0000899243-23-014999 · doc4.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 4,153 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). F2 · balance_after: Includes 1,709 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| May 02, 2023 Filed Jun 9, 2023 01:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 1,553 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-014999 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Wife Disclosed balance after: 4,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: Includes 1,709 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 02:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 1,584 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007270 · doc4.xml · derivative · entry 4 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,749 Underlying: Common Stock · 1,584 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full. F4 · derivative.expiration_date: On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 02:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 1,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-007270 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · ownership.direct: Represents 82,133 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 02:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,883 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003084 · doc4.xml · derivative · entry 7 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 3,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F8 · derivative.exercise_date: On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F8 · derivative.expiration_date: On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 02:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003084 · doc4.xml · derivative · entry 6 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 1,165 Underlying: Common Stock · 388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F7 · derivative.exercise_date: On January 27, 2022 (the "Grant Date"), Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. F7 · derivative.expiration_date: On January 27, 2022 (the "Grant Date"), Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 02:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 1,382 | $7.49 | $10,351.18 |
DisclosureSEC source: 0000899243-23-003084 · doc4.xml · nonDerivative · entry 4 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,591 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). F5 · ownership.direct: Represents 81,931 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 02:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-003084 · doc4.xml · nonDerivative · entry 3 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F4 · balance_after: Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 02:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 141 | $7.49 | $1,056.09 |
DisclosureSEC source: 0000899243-23-003084 · doc4.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 1,378 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 02:17 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-003084 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 1,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: Includes 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:45 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 11,975 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001133 · doc4.xml · derivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 11,975 Underlying: Common Stock · 11,975 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:45 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 23,950 | $0.00 Strike: $5.62 | $0.00 |
DisclosureSEC source: 0000899243-23-001133 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 23,950 Underlying: Common Stock · 23,950 shares Expires 2033-01-03 F1 · derivative.exercise_date: This option was granted on January 3, 2023 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 23:03 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 6,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037694 · doc4.xml · derivative · entry 2 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,333 Underlying: Common Stock · 6,333 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "Ganot RSUs"). F3 · derivative.exercise_date: The Ganot RSUs were granted on the Grant Date and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Separation Date (as defined in the Ganot Agreement); provided that in the event of a Change in Control (as defined in the Ganot Agreement) the Ganot RSUs shall accelerate in full. F3 · derivative.expiration_date: The Ganot RSUs were granted on the Grant Date and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Separation Date (as defined in the Ganot Agreement); provided that in the event of a Change in Control (as defined in the Ganot Agreement) the Ganot RSUs shall accelerate in full. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 23:03 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 13,333 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0000899243-22-037694 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2032-12-02 F1 · derivative.exercise_date: This option (the "Ganot Option") was granted on December 2, 2022 (the "Grant Date") and vests in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Separation Date (as defined in that certain Executive Transition and Separation Agreement between the issuer and Mr. Ganot, the "Ganot Agreement"); provided that in the event of a Change in Control (as defined in the Ganot Agreement) the Ganot Option shall accelerate in full. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:37 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 46,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027115 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 46,600 Underlying: Common Stock · 46,600 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 2, 2022 and vest in two equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: The restricted stock units were granted on May 2, 2022 and vest in two equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 10, 2022 Filed Mar 8, 2022 21:39 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 463 | $1.12 | $518.65 |
DisclosureSEC source: 0001209191-22-017114 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 2,518 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 23,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005690 · doc4.xml · derivative · entry 4 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 23,300 Underlying: Common Stock · 23,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 46,400 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-22-005690 · doc4.xml · derivative · entry 3 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 46,400 Underlying: Common Stock · 46,400 shares Expires 2032-01-27 F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 233,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005690 · doc4.xml · derivative · entry 2 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,000 Underlying: Common Stock · 233,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 466,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-22-005690 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,000 Underlying: Common Stock · 466,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 457 | $7.66 | $3,501.12 |
DisclosureSEC source: 0001209191-21-010690 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 3,026 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 10,713 | $6.14 | $65,775.68 |
DisclosureSEC source: 0001209191-21-006067 · doc4.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,199,821 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. F4 · ownership.direct: Represents 1,139,190 shares held by Mr. Ganot as an individual, and 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006067 · doc4.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 71,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date. F6 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 71,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 35,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-006067 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock units convert into common stock on a one-for-one basis. F2 · ownership.direct: Represents 1,149,903 shares held by Mr. Ganot as an individual, and 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,100 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-005639 · doc4.xml · derivative · entry 2 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 8,100 Underlying: Common Stock · 8,100 shares Expires 2031-01-25 F1 · derivative.exercise_date: This option was granted on January 25, 2021 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 438,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-005639 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,000 Underlying: Common Stock · 438,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: This option was granted on January 25, 2021 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:22 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 27,027 | $3.70 | $99,999.90 |
DisclosureSEC source: 0001209191-20-063216 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175,034 F1 · ownership.direct: Represents 1,114,403 shares held by Mr. Ganot as an individual. Represents 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with a right of survivorship. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 299 | $2.44 | $729.83 |
DisclosureSEC source: 0001209191-20-046769 · doc4.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 3,483 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-046769 · doc4.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 0 Underlying: Common Stock · 800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On August 12, 2019, the reporting person's wife was granted 1,600 restricted stock units. The restricted stock units vested in two equal installments on February 12, 2020 and August 12, 2020. F5 · derivative.expiration_date: On August 12, 2019, the reporting person's wife was granted 1,600 restricted stock units. The restricted stock units vested in two equal installments on February 12, 2020 and August 12, 2020. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-046769 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 3,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 21:23 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,124 | $2.42 | $26,910.07 |
DisclosureSEC source: 0001209191-20-043949 · doc4.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,007 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. F4 · ownership.direct: Represents 1,087,376 shares held by Mr. Ganot as an individual, and 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:23 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043949 · doc4.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 35,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 71,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date. F6 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 71,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:23 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 35,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-043949 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock units convert into common stock on a one-for-one basis. F2 · ownership.direct: Represents 1,098,500 shares held by Mr. Ganot as an individual, and 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. Read SEC document |
| July 27, 2020 Filed Sep 14, 2020 20:14 UTC Amendment | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,350 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-20-050272 · doc4a.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 1,350 Underlying: Common Stock · 1,350 shares Expires 2030-07-26 F1 · security: This amendment to the Form 4 filed on July 29, 2020 (the "Original Form 4") is being filed to add a transaction inadvertently omitted from the Original Form 4. The Original Form 4 omitted an option grant to the reporting person's wife. F2 · derivative.exercise_date: This option was granted on July 27, 2020 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| February 14, 2020 Filed Feb 15, 2020 00:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Tax withholdingCommon Stock | 293 | $3.15 | $922.95 |
DisclosureSEC source: 0001209191-20-009823 · doc4.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 2,937 Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Unit · Derivative | 800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009823 · doc4.xml · derivative · entry 5 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 2,430 Underlying: Common Stock · 800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On August 12, 2019, the reporting person's wife was granted 1,600 restricted stock units. The restricted stock units vest in two equal installments on February 12, 2020 and August 12, 2020. F4 · derivative.expiration_date: On August 12, 2019, the reporting person's wife was granted 1,600 restricted stock units. The restricted stock units vest in two equal installments on February 12, 2020 and August 12, 2020. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:20 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-009823 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 3,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 22:53 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 2,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008912 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 2,430 F1 · shares: The reported transaction involved the reporting person's wife's receipt of a grant of restricted stock units representing 2,430 shares of common stock. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Unit · Derivative | 71,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005404 · doc4.xml · derivative · entry 2 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2030-01-27 F2 · derivative.exercise_date: The restricted stock units will vest in 2 installments. Fifty percent will vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date and will vest automatically as to 100% of the unvested portion of such restricted stock unit grant upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 142,000 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001209191-20-005404 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,000 Underlying: Common Stock · 142,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: This option was granted on January 27, 2020 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| January 27, 2020 Filed Feb 12, 2020 22:49 UTC Amendment | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,320 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001209191-20-008909 · doc4a.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 4,320 Underlying: Common Stock · 4,320 shares Expires 2030-01-27 F1 · security: This amendment to the Form 4 filed on January 29, 2020 (the "Original Form 4") is being filed to add a transaction inadvertently omitted from the Original Form 4. The Original Form 4 omitted an option grant to the reporting person's wife. F2 · derivative.exercise_date: This option was granted on January 27, 2020 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-045880 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · Wife Disclosed balance after: 1,600 Underlying: Common Stock · 1,600 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Solid Biosciences Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest in two equal installments on February 12, 2020 and August 12, 2020. Vested shares will be delivered to the reporting person on the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units vest in two equal installments on February 12, 2020 and August 12, 2020. Vested shares will be delivered to the reporting person on the applicable vesting date. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 20:26 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 21,505 | $4.65 | $99,998.25 |
DisclosureSEC source: 0001209191-19-043483 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,631 F1 · ownership.direct: Represents 1,063,000 shares held by Mr. Ganot as an individual. Represents 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with a right of survivorship. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 22:08 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0000899243-19-001959 · doc4.xml · derivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option was granted on January 23, 2019 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:14 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 19,100 | $31.06 | $593,318.58 |
DisclosureSEC source: 0000899243-18-029304 · doc4.xml · nonDerivative · entry 2 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,126 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.48, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. F5 · balance_after: Represents 1, 041,495 shares held by Mr. Ganot as an individual. Represents 60,631 shares held by Mr. Ganot and Ms. Annie Ganot as joint tenants with a right of survivorship. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 21:14 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 30,900 | $30.70 | $948,614.55 |
DisclosureSEC source: 0000899243-18-029304 · doc4.xml · nonDerivative · entry 1 Ganot Ilan · CIK 0001727460 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,121,226 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.995, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. F4 · balance_after: Represents 1,060,595 shares held by Mr. Ganot as an individual. Represents 60,631 shares held by Mr. Ganot and Ms. Annie Ganot as joint tenants with a right of survivorship. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.